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Fatty acids are of paramount importance to all cells, since they provide energy, function as
signaling molecules, and sustain structural integrity of cellular membranes. In the nervous
system, where fatty acids are found in huge amounts, they participate in its development
and maintenance throughout life. Growing evidence strongly indicates that fatty acids in
their own right are also implicated in pathological conditions, including neurodegenerative
diseases, mental disorders, stroke, and trauma. In this review, we focus on recent studies
that demonstrate the relationships between fatty acids and function and dysfunction of
the nervous system. Fatty acids stimulate gene expression and neuronal activity, boost
synaptogenesis and neurogenesis, and prevent neuroinﬂammation and apoptosis. By
doing so, they promote brain development, ameliorate cognitive functions, serve as
anti-depressants and anti-convulsants, bestow protection against traumatic insults, and
enhance repairing processes. On the other hand, unbalance between different fatty acid
families or excess of some of them generate deleterious side effects, which limit the
translatability of successful results in experimental settings into effective therapeutic
strategies for humans. Despite these constraints, there exists realistic evidence to consider
that nutritional therapies based on fatty acids can be of beneﬁt to several currently incurable
nervous system diseases.
Keywords: monounsaturated fatty acid, neurodegenerative disease, neurological disease, peripheral nerve,
saturated fatty acid, polyunsaturated fatty acid
INTRODUCTION
Fatty acids represent a class of lipids that are crucial components of
all mammalian cells. They display a variety of biological functions
to maintain vital cellular processes at various levels. Thus, fatty
acids provide energy, function as signaling molecules, and sustain
structural integrity of cellular membranes. They are of particular
importance for the nervous system for two major reasons. First,
the nervous system possesses a very high concentration of fatty
acids, second only to adipose tissue (Etschmaier et al., 2011). Sec-
ond, these fatty acids participate actively both in the development
of the nervous system during embryonic and early postnatal life,
and in its maintenance throughout adulthood and natural aging
(Uauy and Dangour, 2006; Rombaldi Bernardi et al., 2012). Along
with these actions, currently incurable pathological conditions of
the nervous system, including neurodegenerative diseases, mental
disorders, stroke, and trauma, involve deregulated contents of fatty
acids. It is therefore believed that these changes contribute in their
own right by as yet incompletely understood mechanisms to those
pathological processes. In consequence, the roles of fatty acids in
health and disease of the nervous system have been intensively
investigated in the last few decades. In this piece of work, we focus
mainly on studies published during the last ﬁve years to show the
diversity in the fatty acids implicated in function and dysfunction
of the nervous system. The detailed mechanisms of action of fatty
acids at the molecular level are not treated in this article, since they
are the subject of other recently published reviews (Georgiadi and
Kersten, 2012; Yamashima, 2012).
SOME ASPECTS OF THE BIOCHEMISTRY OF FATTY ACIDS
According to the IUPACdeﬁnition, fatty acids are“aliphaticmono-
carboxylic acids derived from or contained in esteriﬁed form in
an animal or vegetable fat, oil or wax” (IUPAC, 1997). Naturally
occurring fatty acids mostly consist of an unbranched 4–28 car-
bon chain that is usually composed of an even number of carbon
atoms. On the basis of the carbon chain length, fatty acids are
classiﬁed into short- (less than six carbon atoms), medium- (6–12
carbon atoms), long- (14–22 carbon atoms), and very long chain
fatty acids (more than 22 carbon atoms). Fatty acids in which the
aliphatic chain is fully composed of single bonds between carbon
atoms are named as saturated fatty acids (SFAs), whereas fatty
acids with one or more than one carbon–carbon double bond are
called unsaturated fatty acids. Based on the number of double
bonds, unsaturated fatty acids are further divided into mono-
unsaturated fatty acids (MUFAs) and polyunsaturated fatty acids
(PUFAs; Table 1). Long chain SFAs have relatively high melt-
ing points that make them to appear solid at room temperature.
Therefore, the body possesses a mechanism to introduce double
bonds in the carbon chain, which lowers the melting point and
permits functioning in a physiological environment. There are
four fatty acid desaturases documented in humans that selectively
catalyze the introduction of a double bond in different positions
of the carbon chain. -9 desaturase, also known as stearoyl-CoA
desaturase (SCD), is charged with synthesizing MUFAs, mainly
palmitoleic acid (16:1) and oleic acid (18:1), by introducing a dou-
ble bond between carbon atoms nine and 10 from the carboxylic
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Table 1 | Most typical fatty acids.
Systematic name Common name Abbreviation C:D n-X1
Saturated fatty acids (SFAs)
Butanoic Butyric 4:0
Hexanoic Caproic 6:0
Octanoic Caprylic 8:0
Decanoic Capric 10:0
Dodecanoic Lauric 12:0
Tetradecanoic Myristic 14:0
Hexadecanoic Palmitic 16:0
Octadecanoic Stearic 18:0
Eicosanoic Arachidic 20:0
Docosanoic Behenic 22:0
Tetracosanoic Lignoceric 24:0
Mono-unsaturated fatty acids (MUFAs)
cis-9-Hexadecenoic Palmitoleic 16:1
cis-9-Octadecenoic Oleic 18:1
cis-13-Docosenoic Erucic 22:1
cis-15-Tetracosenoic Nervonic 24:1
Polyunsaturated fatty acids (PUFAs)
cis-9,cis-12-cis-15-Octadecatrienoic α-Linolenic ALA 18:3 n-3
cis-6,cis-9,cis-12,cis-15-Octadecatetraenoic Stearidonic SDA 18:4 n-3
cis-8,cis-11,cis-14,cis-17-Eicosatetraenoic Eicosatetraenoic ETE 20:4 n-3
cis-5, cis-8,cis-11,cis-14,cis-17-Eicosapentaenoic Eicosapentaenoic EPA 20:5 n-3
cis-7,cis-10,cis-13,cis-16, cis-19-Docosapentaenoic Docosapentaenoic DPA 22:5 n-3
cis-4,cis-7,cis-10,cis-13,cis-16,cis-19-Docosahexaenoic Docosahexaenoic DHA 22:6 n-3
cis-9,cis-12-Octadecadienoic Linoleic LA 18:2 n-6
cis-6,cis-9,cis-12-Octadecatrienoic γ-Linolenic GLA 18:3 n-6
cis-8,cis-11,cis-14-Eicosatrienoic Dihomo-γ-linolenic DHGLA 20:3 n-6
cis-5,cis-8,cis-11,cis-14-Eicosatetraenoic Arachidonic AA 20:4 n-6
cis-7,cis-10,cis-13,cis-16-Docosatetrtaenoic Docosatetraenoic 22:4 n-6
cis-4,cis-7,cis-10,cis-13,cis-16-Docosapentaenoic Docosapentaenoic 22:5 n-6
1This nomenclature designates the number of carbon atoms in the fatty acid (C), the number of double bonds (D), and the position of the ﬁrst double bond counting
from the terminal methyl carbon (n-X).
acid end (Figure 1; Enoch et al., 1976). -4,-5, and -6 desat-
urases introduce a double bond at carbon positions 4, 5, and 6,
respectively, and work cooperatively with elongases, which are
responsible for the extension of the aliphatic chain. The combined
actions of desaturases and elongases are implicated in the synthesis
of PUFAs (Nakamura and Nara, 2004).
According to the position of the ﬁrst double bond from the
methyl end of the fatty acid chain, the most important PUFAs for
humans can be divided into two families: n-6 and n-3 PUFAs.
Linoleic acid (LA, 18:2 n-6) is the parent fatty acid of n-6
PUFAs, which produces principally arachidonic acid (AA, 20:4 n-
6), whereas α-linolenic acid (ALA, 18:3 n-3) is the parent fatty acid
of n-3 PUFAs, which gives rise mainly to eicosapentaenoic acid
(EPA, 20:5 n-3) and subsequently docosahexaenoic acid (DHA,
22:6 n-3; Figure 1). Both LA (18:2 n-6) andALA (18:3 n-3) cannot
be synthesized indigenously by the human body, so that they must
be supplied with food, and such fatty acids are termed as essential
fatty acids (Ruzickova et al., 2004; Lands, 2012). In spite of the fact
that the body is able to metabolize these essential fatty acids, the
efﬁciency of conversion is low. Hence, the availability not only of
essential precursors but also of some of their metabolites, such as
EPA (20:5 n-3) and DHA (22:6 n-3), greatly depends on dietary
support (Brenna et al., 2009). Alternatively, PUFAs can also be
made available by enzymatic processing of membrane phospho-
lipids by phospholipases (Lee et al., 2011). Whatever pathway is
involved, several PUFAs can be metabolized by cyclo-oxygenases,
lipo-oxygenases, or cytochrome P450 mono-oxygenases to pro-
duce other compounds with important biological functions. AA
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FIGURE 1 | Biosynthesis of fatty acids. Medium- to long chain SFAs
are successively transformed by the action of elongases (E) into palmitic
acid (16:0), which is then either elongated to stearic acid (18:0), and other
long chain SFAs, or desaturated, together with stearic acid (18:0), by Δ9
desaturase to produce de novo MUFAs of the n-7 and n-9 series, such as
palmitoleic acid (16:1) and oleic acid (18:1). In the case of PUFAs, Δ6 and
Δ5 desaturases work cooperatively with elongases to introduce double
bonds and extend the aliphatic chain in a successive manner, from
ALA (18:3 n-3) to EPA (20:5 n-3) in the n-3 series, and from LA (18:2 n-6)
to AA (20:4 n-6) in the n-6 series. Afterward, these end products are
further elongated, desaturated, and submitted to peroxisomal β-
oxidation (all three steps indicated by OX) to yield DHA (22:6 n-3) and
docosapentaenoic acid (22:5 n-6), respectively. Finally, AA (20:4 n-6)
is the precursor of potent pro-inﬂammatory eicosanoids. EPA (20:5 n-3)
produces less potent (dashed arrow) eicosanoids and, together with DHA
(22:6 n-3), gives rise to docosanoids with anti-inﬂammatory properties (i.e.,
resolvins and protectins). GLA, γ-linolenic acid; DHGLA, dihomo-γ-linolenic
acid.
(20:4 n-6) and, to a lesser extent, EPA (20:5 n-3) are trans-
formed into potent pro-inﬂammatory eicosanoids. Additionally,
EPA (20:5 n-3) and DHA (22:6 n-3) generate opposing anti-
inﬂammatory docosanoids, including resolvins and protectins
such as neuroprotectin-D1 (NPD1; Bazan, 2009; Figure 1).
EVIDENCE OF THE IMPORTANCE OF FATTY ACIDS FOR
HEALTH AND DISEASE OF THE NERVOUS SYSTEM
FATTY ACIDS AND BRAIN DEVELOPMENT
Mother’s own resources, via placenta and milk, provide most of
the n-3 PUFAs necessary for brain development during fetal and
early postnatal life. Due to this high demand of the developing ner-
vous system in the progeny, maternal brain levels of DHA (22:6
n-3) exhaust during pregnancy and lactation period (Chen and
Su, 2012). Thus, enhanced provision or adequate supply of n-
3 PUFAs at these stages can yield positive effects on offspring
brain development. For instance, increased expression of neuron
speciﬁc enolase, glial ﬁbrillary acidic protein, andmyelinbasic pro-
tein was observed in pups from mice fed on n-3 PUFA enriched
diet, administered from two months prior to mouse conception
to end of lactation period (Tian et al., 2011). Similarly, postna-
tal supplementation of ALA (18:3 n-3), the parent precursor of
n-3 PUFAs, enhanced cell proliferation and early neuronal differ-
entiation, while its deprivation resulted in increased proportion
of apoptosis in the dentate gyrus of unweaned pups. This ame-
liorating effect was offset by maternal ALA (18:3 n-3) deﬁciency
during gestation period, suggesting that ALA (18:3 n-3) is not
only required at postnatal stages but is also essential for fetal brain
development (Niculescu et al., 2011). Importantly, such diets given
at perinatal stagesmay have long lasting consequences in the adult-
hood. Thus, the abundance of n-3 PUFAs in the diet of pregnant
females revealed essential for the development of the glutamatergic
system and normal behavior performance in the adult offspring
(Moreira et al., 2010a). Also, motor coordination was ameliorated
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in adulthood when rats were fed on DHA (22:6 n-3) and EPA
(20:5 n-3) supplementation starting from gestation stage to post-
natal age of 90 days (Coluccia et al., 2009). Finally, n-3 PUFA
enriched diets also improved reference and working memory in
offspring rats when supplied to mother at gestation stage (Chung
et al., 2008).
Frequently, the impact of dietary fatty acids depends on a bal-
ance between different types. In a study to assess the effects of
quality and quantity of several high fat diets, mice were nourished
with various concentrations and types of fats mingled with nor-
mal chow. It was noticed that these diets not only modiﬁed the
lipid proﬁle in brain but also altered spatial memory and learn-
ing ability of the pups in a different manner (Yu et al., 2010). In
another study, when mice were fed on diets supplemented with
either SFAs or MUFAs, MUFAs promoted insulin sensitivity and
cortical activity while SFAs did not (Sartorius et al., 2012). Lastly,
it is noteworthy that the intake of sufﬁcient quantity of MUFAs
prevented the age related deletion of mitochondrial DNA in the
brain of aged animals (Ochoa et al., 2011).
FATTY ACIDS AND NEURODEGENERATIVE DISORDERS
The altered amounts of different classes of fatty acids in the ner-
vous system may contribute positively or negatively to any given
neuropathological process (Table 2). Using APP-C99-transfected
COS-7 cells, a cellular model of Alzheimer’s disease-like degen-
eration, a study was carried out to investigate the class of fatty
acids that was thought to inﬂuence the production of Aβ peptide,
which is a major neuropathological hallmark of disease. It was
Table 2 | Changes in brain fatty acid composition in pathological conditions.
Fatty acid Disease Tendency Reference1
Saturated fatty acids (SFAs)
Myristic (14:0) Depression Down Conklin et al. (2010)
Palmitic (16:0) Alzheimer Up Fraser et al. (2010)
Palmitic (16:0) Parkinson Up Fabelo et al. (2011)
Palmitic (16:0) Depression Down Conklin et al. (2010)
Palmitic (16:0) Depression Up Hamazaki et al. (2012)
Stearic (18:0) Alzheimer Down Fraser et al. (2010)
Stearic (18:0) Parkinson Up Fabelo et al. (2011)
Stearic (18:0) Depression Down Conklin et al. (2010)
Mono-unsaturated fatty acids (MUFAs)
Palmitoleic (16:1) Alzheimer Up Astarita et al. (2011)
Palmitoleic (16:1) Depression Down Conklin et al. (2010)
Oleic (18:1) Alzheimer Down Martín et al. (2010)
Oleic (18:1) Alzheimer Up Fraser et al. (2010)
Oleic (18:1) Alzheimer Up Astarita et al. (2011)
Oleic (18:1) Depression Up Hamazaki et al. (2012)
Erucic (22:1) Alzheimer Up Astarita et al. (2011)
Nervonic (24:1) Alzheimer Up Astarita et al. (2011)
Polyunsaturated fatty acids (PUFAs)
EPA (20:5 n-3) Depression Down Lin et al. (2010)
DPA (22:5 n-3) Depression Down Conklin et al. (2010)
DHA (22:6 n-3) Alzheimer Down Martín et al. (2010)
DHA (22:6 n-3) Parkinson Down Fabelo et al. (2011)
DHA (22:6 n-3) Depression Down Conklin et al. (2010)
DHA (22:6 n-3) Depression Down Lin et al. (2010)
LA (18:2 n-6) Depression Down Conklin et al. (2010)
AA (20:4 n-6) Parkinson Down Fabelo et al. (2011)
AA (20:4 n-6) Depression Down Conklin et al. (2010)
Docosatetraenoic (22:4 n-6) Depression Down Conklin et al. (2010)
Docosatetraenoic (22:4 n-6) Schizophrenia Down Hamazaki et al. (2012)
1This table summarizes recent studies cited in the text. It is concluded that, whatever disease condition is considered, PUFA levels were systematically decreased,
whereas MUFA amounts often appeared increased. In contrast, there was no clear-cut tendency in the changes of the proportions of SFAs.
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shown that palmitic acid (16:0), stearic acid (18:0), upstream n-3
PUFAs, and AA (20:4 n-6) triggered higher secretion of Aβ pep-
tide compared to long chain downstream n-3 PUFAs and MUFAs
(Amtul et al., 2011a). These ﬁndings were corroborated in vivo by
using a transgenic mouse model of early-onset Alzheimer’s disease
that expresses the double-mutant form of human APP, which is
the precursor protein responsible for the synthesis of Aβ peptide.
Decreased levels ofAβpeptide and less accumulation in the formof
amyloid plaqueswere observed in the brain of mice nourishedwith
a diet enriched in n-3 PUFAs, mainly DHA (22:6 n-3; Amtul et al.,
2011a). Not only extraneously supplied but endogenously syn-
thesized n-3 PUFAs can suppress the synthesis of Aβ peptide and
the formation of amyloid plaques. Lebbadi et al. (2011) crossed
3xTg-AD mice, a model of Alzheimer’s disease, with transgenic
mice expressing -3 desaturase (Fat-1) from Caenorhabditis ele-
gans, which endogenously converts n-6 PUFAs into n-3 PUFAs.
It was observed that the double transgenic 3xTg-AD/Fat-1 mice
had increased brain levels of DHA (22:6 n-3) and lower levels of
Aβ peptide. Similarly, MUFAs, mainly oleic acid (18:1 n-9), were
also shown to inhibit the production of Aβ peptide and amyloid
plaques both in vitro and in vivo (Amtul et al., 2011b). In contrast,
n-6 PUFAs, such as AA (20:4 n-6), aggravated Alzheimer’s disease
neuropathology, by increasing the synthesis of Aβ peptide (Amtul
et al., 2012).
The results obtained in experimental models of Alzheimer’s
disease have been conﬁrmed, at a certain extent, by studies per-
formed on human brain. Thus, decreased levels of PUFAs and
MUFAs, particularly DHA (22:6 n-3) and oleic acid (18:1 n-9),
respectively, were observed in the brain of Alzheimer’s disease
patients (Martín et al., 2010). However, other studies reported that,
although the abundance of DHA (22:6 n-3) varied highly among
patients, the mean quantity of this PUFA did not differ signiﬁ-
cantly when compared to healthy brains (Fraser et al., 2010). This
study also showed that levels of stearic acid (18:0) were reduced
remarkably in frontal and temporal cortex, while those of oleic
acid (18:1 n-9) were increased in both parts; also, levels of palmitic
acid (16:0) appeared increased in the parietal cortex (Fraser et al.,
2010). These a priori puzzling abnormalities in MUFAs could be a
result of alterations in the expression of MUFA synthesizing genes.
Thus, levels of MUFAs in hippocampus, frontal cortex and tem-
poral cortex were elevated in Alzheimer’s disease patients, as was
the expression of the SCD isomers SCD1, SCD5a, and SCD5b.
In addition, the ratio of MUFAs to SFAs, an index of desaturase
activity, was reported to be negatively correlated with the degree
of cognitive performance (Astarita et al., 2011).
Less is known about the changes of fatty acids in other neurode-
generative conditions. Fabelo et al. (2011) reported that lipid rafts
from brain cortices of patients with Parkinson disease displayed
signiﬁcantly decreased levels of n-3 and n-6 PUFAs, particularly
DHA (22:6 n-3) and AA (20:4 n-6), respectively, while SFAs,
mainly palmitic acid (16:0) and stearic acid (18:0), were noted
augmented, as compared to control subjects. In another study,
the effects of diets rich in n-3 or n-6 PUFAs were assessed on
cuprizone-induced experimental demyelination, an animal model
formultiple sclerosis. It was observed that n-3 PUFAs fromvarious
sources affected the pathological phenotype differently; for exam-
ple, a diet containing n-3 PUFAs from salmon ameliorated the
behavioral deﬁcits induced by cuprizone, whereas a diet contain-
ing n-3 PUFAs from cod affected similarly as n-6 PUFA enriched
or control diet did, suggesting that not only the type of PUFA
but its origin is also to consider when prescribing a diet based
remedy (Torkildsen et al., 2009). Contrasting these ﬁndings, other
studies did not corroborate the protective effects of n-3 PUFAs
against multiple sclerosis and concluded that neither n-3 nor n-6
PUFAs had any effect on disease progression or remedial inﬂuence
(Wergeland et al., 2012). Moreover, dietary administration of EPA
(20:5 n-3) even accelerated disease progression in mice expressing
a mutated form of Cu/Zn-superoxide dismutase (SOD1), which is
amodel of neuromuscular degeneration as caused by amyotrophic
lateral sclerosis (Yip et al., 2013).
FATTY ACIDS AND TRAUMATIC INJURY TO THE NERVOUS SYSTEM
Several recent studies have provided evidence that n-3 PUFAs can
exert protection against neuronal injury triggered by hypoxia or
ischemia. In neonates, these fatty acids protected neurons follow-
ing hypoxia/ischemia by modulating the microglial inﬂammatory
response through inhibition of the nuclear factor-κB (NF-κB)
dependent pathway (Zhang et al., 2010). However, it is impor-
tant to mention that consistent increased intake of n-3 PUFAs can
also affect adversely in some cases. In this respect, a diet rich in
EPA (20:5 n-3) and DHA (22:6 n-3) enhanced the risk for intrac-
erebral hemorrhagic stroke in rats, and caused oxidative damage
to the brain, probably due to the fact that a high PUFA con-
tent increased the danger of lipid peroxidation. Alternatively, n-3
PUFA intake was reported to affect blood viscosity, vasoconstric-
tion, platelet aggregation, and blood clotting ultimately leading to
hemorrhaging (Park et al., 2009).
There is also evidence that certain fatty acids have the poten-
tial to improve the recovery of the injured spinal cord. Hirakawa
et al. (2010) reported that trans-2-decenoic acid ethyl ester, a
medium-chain fatty acid derivative, increased the expression of
extracellular signal-regulated protein kinases 1 and 2 (ERK1/2)
in cultured cortical neurons and at the site of injury in a rat
spinal cord injury model. Indeed, the administration of trans-
2-decenoic acid ethyl ester ameliorated functional recovery and
reduced lesion size in response to injury, by increasing the expres-
sion of ERK1/2, brain-derived neurotrophic factor (BDNF), and
anti-apoptotic Bcl-2. Similarly, DHA (22:6 n-3) pre-treatment in
an acute spinal cord injury model diminished the extent of func-
tional deﬁcits as compared to that observed in the control group,
and this protective effect was associated with increased survival of
precursor cells, sparing of white matter and axonal preservation
(Figueroa et al., 2012; Lim et al., 2013b). In the same way, mice
carrying the Fat-1 transgene for boosting endogenous synthesis of
n-3 PUFAs showed better outcome after spinal cord injury (Lim
et al., 2013a). Finally, in relation to diabetes, it was shown that
the augmentation of epoxy-fatty acid resources, as obtained by
inhibiting soluble epoxide hydrolase, resulted in a dose dependent
anti-allodynic effect on neuropathic pain due to glucose toxicity
(Inceoglu et al., 2012).
FATTY ACIDS AND NEUROLOGICAL DISORDERS
Particular changes in brain fatty acid composition appear to be
intimately connected to a series of neurological diseases, as recently
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reported in several studies. Thus, Conklin et al. (2010) observed
a reduction in the quantity of both saturated and unsaturated
fatty acids of various types, including n-3 and n-6 PUFAs, in
the cingulate cortex of depressive patients. Similar alternations
in n-3 PUFAs, including EPA (20:5 n-3) and DHA (22:6 n-3),
were also shown by others (Lin et al., 2010). In another study,
it was noticed that the altered concentrations of MUFAs and
PUFAs were region-speciﬁc. In fact, no changes in n-3 and n-
6 PUFAs were found in hippocampus and orbitofrontal cortex
of patients with depression but concentrations of MUFAs, such
as oleic acid (18:1 n-9), and SFAs, such as palmitic acid (16:0),
appeared augmented (Hamazaki et al., 2012). A partial conﬁr-
mation of these ﬁndings emerged from another study showing
lowered expression of genes involved in PUFA and MUFA synthe-
sis in the frontal cortex of depressed patients (McNamara and
Liu, 2011). It is also noteworthy that lifelong n-3 PUFA deﬁ-
ciency perturbed normal endocannabinoid function in prelimbic
prefrontal cortex and accumbens, and this effect was related to
impaired emotional behavior (Lafourcade et al., 2011). Although
less investigated, several studies also detected changes in fatty acids
in patients with schizophrenia. A decrease in docosatetraenoic
acid (22:4 n-6) was observed in the nuclei of the amygdala of these
patients but other PUFAs, including DHA (22:6 n-3) andAA (20:4
n-6), remained unchanged (Hamazaki et al., 2010, 2012). Interest-
ingly, the decrease in totalmembrane PUFAs found in erythrocytes
of young patients with schizophrenia correlated with the degree
of demyelination in brain white matter (Peters et al., 2009).
Lastly, several lines of evidence support the anticonvulsant
effects of certain fatty acids in animal models of epileptogenesis,
and the administration of PUFA enriched diets has been envisaged
to treat epileptogenic convulsions. Using the pentylenetetrazol-
induced epilepsy ratmodel, Porta et al. (2009) showed that a PUFA
containing diet increased the threshold level for pentylenetetra-
zol to induce convulsions. A contemporary study conﬁrmed that
rats nourished with n-3 PUFAs exhibited greater resistance to
pentylenetetrazol-induced seizures (Taha et al., 2009). In the kin-
dling model of epilepsy, intracerebroventricular injection of DHA
(22:6 n-3), or its derivative NPD1, limited the progression in the
hippocampus of the electrically induced neuronal hyperexcitabil-
ity characteristic of seizures (Musto et al., 2011). In contrast, other
studies did not corroborate these ﬁndings, since DHA (22:6 n-
3) or EPA (20:5 n-3) showed neither anticonvulsant activity nor
protection against pentylenetetrazol-induced seizures (Willis et al.,
2009).
CELLULAR ROLES OF FATTY ACIDS IN THE NERVOUS SYSTEM
ACTIONS OF FATTY ACIDS IN THE HIPPOCAMPUS
Many recent studies have investigated the implication of fatty acids
in learning and memory processes occurring in the hippocampus
(Figure 2). In general, n-3 PUFAs were shown to foster neuronal
activity and hence counteract memory deﬁcits. It is well known
that increased c-Fos expression is an indicator of neuronal activ-
ity in response to extracellular signals like growth factors, and it
is initiated when neurons ﬁre action potentials. Commonly, the
activity of c-Fos decreases as age extends and spatial memory goes
off. Provision of n-3 PUFAs restored c-Fos expression in the hip-
pocampus, and enhanced neuronal activity ultimately leading to
the amelioration of memory deﬁcits in aged mice (Labrousse et al.,
2012). Dietary DHA (22:6 n-3) also enhanced the expression of F-
ATPase involved inmitochondrial ATP synthesis in the CA1 region
of the hippocampus, whereas its deﬁciency led to decreased glu-
cose transporter expression and defective glucose transport in the
cerebral cortex (Harbeby et al., 2012). The stimulatory action of
n-3 PUFAs on gene expression also appears to affect neurotrans-
mission. In fact, recent proteomics studies performed on mouse
brain deﬁcient in DHA (22:6 n-3) revealed a loss of synaptic pro-
teins associated with altered synaptic transmission (Sidhu et al.,
2011). In contrast, expression of vesicular glutamate transporters
1 and 2, which are implicated in glutamatergic neurotransmission,
was increased in response to ALA (18:3 n-3) exposure (Blondeau
et al., 2009). Similarly, DHA (22:6 n-3) provision to rats with trau-
matic brain injury enhanced learning ability, by modulating the
expression levels of synapsin-1, cAMP response element-binding
protein-1 and calcium/calmodulin-dependent protein kinase-2 in
the hippocampus of treated animals (Wu et al., 2008, 2011). DHA
(22:6 n-3) also ameliorated spatial memory in rats by increas-
ing the expression of subtypes of endocannabinoid/endovanilloid
receptors (Pan et al., 2011). Last, n-3 PUFAs augmented the
expression of a series of transcription factors involved in learning
and memory, including retinoic acid receptor, retinoic X recep-
tor and peroxisome proliferator-activated receptor (Dyall et al.,
2010).
Many positive actions of DHA (22:6 n-3), and likely other n-3
PUFAs, may therefore converge to enhance synaptic transmission,
and ameliorate spatial learning and memory (Connor et al., 2012).
In a mouse model of systemic lupus erythematosus and Sjögren’s
syndrome, which is characterized by behavioral abnormalities,
reduced aged hippocampal neurogenesis and loss of long-term
potentiation (LTP), the dietary supplementation with n-3 PUFAs
corrected LTP at synapses in themedial perforant pathway/dentate
gyrus and enhanced the amount of adult-born neurons in the hip-
pocampus (Crupi et al., 2012). Similarly, docosapentaenoic acid
(DPA,22:5 n-3) also ameliorated hippocampal function by attenu-
ating the reduction in LTP in aged brain (Kelly et al., 2011). Finally,
in vitro studies showed that treatment of differentiated PC12 cells
with EPA (20:5 n-3) resulted in activation of the neuroprotec-
tive PI3-kinase/Akt signaling pathway, a mechanism that might
account for the increase in LTP observed in vivo following EPA
(20:5 n-3) treatment (Wu et al., 2008; Kawashima et al., 2010).
In Alzheimer’s disease, Aβ peptide induces neuronal apopto-
sis through degradation of the adaptor protein insulin receptor
substrate-1 in a c-Jun N-terminal kinase (JNK)-dependent man-
ner. An n-3 PUFA enriched diet prevented the phosphorylation
of JNK, and ultimately protected neurons from death in vitro and
improved cognitive deﬁcit in vivo (Ma et al., 2009). Also, lower
levels of phosphorylated tau protein and improved brain function
were observed by crossing 3xTg-AD mice with Fat-1 express-
ing mice to enhance the endogenous production of n-3 PUFAs
(Lebbadi et al., 2011). Nevertheless, it is noteworthy that 12/15-
lipo-oxygenase adversely affected Alzheimer’s disease pathology
by synthesizing pro-inﬂammatory and pro-oxidant hydroperox-
yacids resulting from the oxidation of PUFAs, so that genetic
ablation of this enzyme ameliorated cognitive function (Yang et al.,
2010).
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FIGURE 2 | Multiple effects of fatty acids in the hippocampus. n-3 and n-6 PUFAs exert a variety of positive actions that promote formation, storage and
processing of learning and memory in the hippocampus. In contrast, SFAs display rather negative actions. Green arrows indicate stimulatory effects while
orange arrows represent inhibitory effects.
Neuroinﬂammation is one of the distinctive features of aged or
diseased brain, as demonstrated by the activation of glial cells and
the increase in the expression of a variety of pro-inﬂammatory
factors. In this respect, it was reported that n-3 PUFA provi-
sion restored spatial memory loss in aged animals by suppressing
pro-inﬂammatory interleukin-1β and reverting to normal the
morphology of microglia and astrocytes in the hippocampus
(Labrousse et al., 2012; Park et al., 2012). n-3 PUFAs also yielded
protecting effects to neurons by blocking microglia activation in
a transgenic mouse model of systemic lupus erythematosus and
Sjögren’s syndrome (Crupi et al., 2012). In the same way, DPA
(22:5 n-3) inactivated microglia attenuating neuroinﬂammation
and counteracting spatial learning deﬁcit in aged brain (Kelly et al.,
2011). Contrary to theprotective effects of PUFAs, SFAs stimulated
the secretion of pro-inﬂammatory cytokines and induced apop-
tosis in astrocytes. Particularly, palmitic acid (16:0), lauric acid
(12:0), and stearic acid (18:0) triggered the secretion of tumor
necrosis factor-α (TNF-α) and interleukin-6 by engaging toll-like
receptor-4 (TLR-4). Moreover, palmitic acid (16:0) also activated
caspase-3 and modiﬁed the Bax/Bcl-2 ratio in these glial cells for
apoptotic demise. Interestingly, these pro-inﬂammatory actions of
SFAs could be reverted by n-3 PUFAs like DHA (22:6 n-3; Gupta
et al., 2012; Wang et al., 2012).
Another way by which n-3 PUFAs can afford neuroprotection
is by preventing apoptosis. The mouse model of infantile neu-
ronal ceroid lipofuscinosis, a neurodegenerative disease caused
by palmitoyl-protein thioesterase-1 (PPT1) deﬁciency, manifests
enhanced endoplasmic reticulum- and oxidative stress that lead
to apoptotic cell demise. In PPT1-deﬁcient cells from such mice,
intervention of n-3 PUFAs attenuated stress and repressed apop-
totic death casting a protection to neuronal cells (Kim et al., 2010;
Wu et al., 2011). Similarly, differentiated PC12 cells treated with
EPA (20:5 n-3) showed lower rates of apoptosis and suppressed
activity of the apoptotic effector caspase-3 (Boudrault et al., 2009;
Kawashima et al., 2010). Conjugated LA (18:2 n-6) also protected
neurons from mitochondrial dysfunction and demise. Treatment
of cortical neurons with this fatty acid following excitotoxic glu-
tamate exposure resulted in decreased glutamate-induced loss
of mitochondrial function, increased Bcl-2 expression and pro-
longed neuronal survival (Hunt et al., 2010). In the same manner,
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administration of ﬁsh oil, that is a rich source of n-3 PUFAs, pro-
tected hippocampal neurons from diabetic insult by precluding
the expression of apoptosis inducing genes in bothCA1 region and
cultured cells, and by increasing the expression of anti-apoptotic
genes, such as Bcl-2 and Bcl-xL (Zhang and Bazan, 2010; Zhao
et al., 2012). Together with caspase-3, ceramides, resulting from
the hydrolysis of sphingomyelin by sphingomyelinase, are well-
known apoptosis inducing factors. Treatment with DPA (22:5 n-3)
inactivated sphingomyelinase and caspase-3 in the hippocampus
of elderly rats (Kelly et al., 2011). On the other hand, n-3 PUFA
withdrawal modulated the phosphorylation of glycogen-synthase
kinase-3β and ERK1/2, predisposing more hippocampal neurons
to damage in an in vitro oxygen and glucose deprivation model of
ischemia (Moreira et al., 2010b). Along with this, a decrease in the
release of PUFAs from cell membranes in the rat hippocampus, as
a result of reduced phospholipase-A2 activity, caused alterations in
membrane ﬂuidity that could account for loss of spatial memory
and cognitive impairment in Alzheimer’s disease (Schaeffer et al.,
2011). However, the protective effects of n-3 PUFAs under certain
conditions seemed to be limited to some of the members of this
class of fatty acids. Thus, onlyDHA(22:6 n-3) offset the expression
of AMPA receptors in the membrane of hippocampal neurons and
attenuated neurotoxicity leading to improved cognitive function.
Other members of the n-3 PUFA family, especially EPA (20:5 n-
3), lacked such a protective effect against AMPA-mediated toxicity
(Ménard et al., 2009).
Synaptogenesis is one of the mechanisms by which memory
process takes place. Hence, the loss of synapses is characteristic
of neurodegenerative conditions and aging. For instance, cortical
or hippocampal neurons incubated with the neurotoxic prion-
derived peptide PrP82–146, and pre-treated with DHA (22:6
n-3) or EPA (20:5 n-3), showed less loss of synaptophysin-1 and
reduced accumulation of prion peptide (Bate et al., 2010). ALA
(18:3 n-3) also stimulated the expression of genes involved in
synaptic function, like VAMP-2, SNAP-25 and synaptophysin-1,
that led to improved stability and physiology of synapses (Blon-
deau et al., 2009). Similarly, the chronic supplementation of n-3
PUFAs yielded anti-depressant effects by increasing the expres-
sion of synaptophysin-1 in the hippocampus (Venna et al., 2009).
However, another studyperformedonSH-SY5Y cells reported that
DHA (22:6 n-3) did not affect the neurotransmission machinery,
as evaluated by the expression of synaptotagmin-1, syntaxin-1A,
and synaptobrevin-1, although the release of noradrenaline by
these cells was enhanced (Mathieu et al., 2010).
Hippocampal neurogenesis also contributes to learning and
memory processes. The mouse model of systemic lupus erythe-
matosus and Sjögren’s syndrome typically exhibits age-dependent
reduced hippocampal neurogenesis. Supplementation of diet with
n-3 PUFAs to these mice enhanced the density of bromodeoxyuri-
dine (BrdU)- and doublecortin positive cells in the hippocampus,
suggesting an ongoing neurogenesis (Crupi et al., 2012). Similar
neurogenesis enhancement was also reported in response to ALA
(18:3 n-3) treatment (Blondeau et al., 2009). In addition, AA (20:4
n-6) even increased neurogenesis at postnatal stages when admin-
istered at gestation period (Maekawa et al., 2009). Several in vitro
studies revealed that not only n-3 PUFA precursors, such as EPA
(20:5 n-3), but also naturally derived metabolites, including the
neurotrophic N-docosahexaenoylethanolamine, stimulated neu-
rogenic differentiation of neural stem cells (Katakura et al., 2013;
Rashid et al., 2013). The importance of the stimulatory role of
PUFAs for neurogenesis is also illustrated by experiments report-
ing increased expression of fatty acid binding proteins (FABPs) in
the ischemic hippocampus. FABPs are carriers of PUFAs in the
cytoplasm, and their expression declines with age in association
with reduced synaptic activity and other cellular functions. CA1
and dentate gyrus regions in the hippocampus showed augmented
levels of FABP-5 and FABP-7 after ischemia, suggesting elevated
transportation of PUFAs in these regions to restore cellular neu-
rophysiology (Liu et al., 2010; Ma et al., 2010). More importantly,
at post-ischemic stages, the subgranular zone in the dentate gyrus
of the hippocampus, a niche of adult neurogenesis, displayed a
concomitant increase in the neuronal expression of FABPs and
the fatty acid receptor GPR40, representing compensatory pro-
cesses of newborn cells (Boneva et al., 2011a,b; Yamashima, 2012).
Finally, it is noteworthy that many of the beneﬁcial actions of
PUFAs on hippocampal function were associated with an increase
in theproductionof BDNF,which is amemberof theneurotrophin
family of growth factors involved in supporting growth, differen-
tiation and survival of neurons (Wu et al., 2008, 2011; Blondeau
et al., 2009; Venna et al., 2009; Avraham et al., 2011; Vines et al.,
2012).
ACTIONS OF FATTY ACIDS IN THE HYPOTHALAMUS
The central regulation of energy balance involves a number of
neuronal circuits in the hypothalamus that either exert anorexic
actions or stimulate food intake. In this respect, it was recently
shown that certain fatty acids could inﬂuence the control of energy
homeostasis by the hypothalamus. In general, dietary supple-
mentation with ﬁsh oil, rich in n-3 PUFAs, normalized several
hypothalamic neurochemical systems in food restricted animals
(Avraham et al., 2011). However, supplementation of diet with
SFAs induced endoplasmic reticulum stress and expression of
cytokines via TLR-4 signaling in the hypothalamus, and this effect
resulted in resistance to anorexigenic signals (Milanski et al., 2009).
At the cellular level, treating hypothalamic mHy-poE-44 cells with
palmitic acid (16:0) increased the expression of the orexigenic
neuropeptide-Y, suggesting that this fatty acid could enhance food
intake (Fick et al., 2011). Moreover, palmitic acid (16:0) faded
insulin signaling and enhanced endoplasmic reticulum stress and
caspase-3 cleavage in the same cell line, which resulted in apop-
tosis in a JNK-dependent manner (Mayer and Belsham, 2010). In
another study, exposure to palmitic acid (16:0) displayed no effects
on insulin resistance and inﬂammatory process activation but cor-
roborated the stimulation of endoplasmic reticulum stress and
apoptosis, along with the activation of mitogen-activated protein
kinase (Choi et al., 2010).
ACTIONS OF FATTY ACIDS IN THE NIGROSTRIATAL PATHWAY
Growing evidence supports a link between the dietary intake of
n-3 PUFAs and the function (or dysfunction) of the nigrostri-
atal pathway involved in the control of movement (Figure 3).
This relationship was particularly investigated in a number of ani-
mal models of Parkinson disease, which is a neurodegenerative
condition primarily characterized by the loss of dopaminergic
Frontiers in Cellular Neuroscience www.frontiersin.org September 2013 | Volume 7 | Article 144 | 8
“fncel-07-00144” — 2013/9/6 — 13:17 — page 9 — #9
Hussain et al. Fatty acids and nervous system
FIGURE 3 | Conflicting effects of n-3 PUFAs in the nigrostriatal pathway.
n-3 PUFAs are commonly endowed with a wide range of helpful effects, as
illustrated by the protective beneﬁt that these fatty acids offer to
dopaminergic neurons in the nigrostriatal tract against apoptotic and
pro-inﬂammatory cues. However, extreme caution should be exercised since
these same PUFAs may not provide complete safety to halt degeneration
induced by parkinsonian toxins or even trigger adverse effects, which
eventually aggravates the extent of the pathological process.
neurons connecting the substantia nigra to the striatum. In
several recent studies, n-3 PUFAs were shown to be beneﬁcial
by reverting disease phenotype. In the MPTP model of Parkin-
son disease, pre-treatment of mice with n-3 PUFAs bestowed
protection by increasing the expression of BDNF and involv-
ing its TrkB receptor (Bousquet et al., 2009; Balanzá-Martínez
et al., 2011). In other studies, it was found that exposure to the
n-3 PUFA ethyl-eicosapentaenoate derivative lowered the expres-
sion of Bax and caspase-3, and enhanced cortical dopamine
levels (Bousquet et al., 2008; Meng et al., 2010). Furthermore,
n-3 PUFAs also yielded protective inﬂuence indirectly, by atten-
uating inﬂammation-causing factors. These fatty acids targeted
the NFκB signaling pathway in microglia to suppress their over-
activated response and hence protect dopaminergic neurons
(Boudrault et al., 2009; Zhang et al., 2010; Ji et al., 2012; Zhou
et al., 2012).
Other ﬁndings, however, did not support the beneﬁcial
effects of n-3 PUFAs on Parkinson disease. It was reported
that treatment with ethyl-eicosapentaenoate, although minimized
pro-inﬂammatory cytokines and yielded positive effects on pro-
cedural memory deﬁcit, it was unable to preclude the loss of
nigrostriatal dopamine in MPTP mice (Shchepinov et al., 2011;
Luchtman et al., 2012). Similarly, the parkinsonian neurotoxin 6-
hydroxydopamine caused lesions in the medial forebrain bundle
of rats and motor deﬁcits that remained unaffected by ﬁsh oil
derived n-3 PUFAs (Delattre et al., 2010). A chronic interven-
tion of a DHA (22:6 n-3) containing diet modiﬁed neither the
number of cortical glial cells nor the expression of α-synuclein,
which is typically involved in disease pathogenesis (Muntané et al.,
2010). The use of different animal models of Parkinson disease
and the different ways of treating these mice to counteract the
pathological process may explain the observed discrepancies. In
this respect, it is important to mention that some studies indi-
cated even adverse effects of n-3 PUFAs on Parkinson disease
pathogenesis. Indeed, the presence of DHA (22:6 n-3) augmented
neuritic injury and astrocytosis in mice transgenic for a Parkin-
son disease causing mutation in human α-synuclein. In addition,
DHA (22:6 n-3) triggered oligomerization of α-synuclein, through
the activation of retinoic X receptor and peroxisome proliferator-
activated receptor-γ2. Interestingly, its withdrawal from diet was
found to be beneﬁcial against the deleterious effects caused by
it provision (Yakunin et al., 2012). Finally, structural and con-
formational modiﬁcations in α-synuclein leading to pathological
aggregation were brought by DHA (22:6 n-3; De Franceschi et al.,
2009, 2011; Bousquet et al., 2011).
ACTIONS OF FATTY ACIDS IN THE PERIPHERAL NERVES
A subset of peripheral sensory neurons expresses transient recep-
tor potential cation channel-A1 (TRPA1), which is involved in
pain and neurogenic inﬂammation. TRPA1 is a target for a vari-
ety of noxious and inﬂammatory irritant substances. In addition,
it was found that n-3 PUFAs could act as a ligand for TRPA1 to
excite sensory neurons and hence regulate their responses in vivo
(Motter and Ahern, 2012). Transient receptor potential vanilloid
cation channel-1 (TRPV1), which is another member of the fam-
ily, is also found mainly in nociceptive neurons of the peripheral
nervous system,where they are involved in transmission andmod-
ulation of pain. In this respect, it was shown that NPD1, which has
anti-inﬂammatory properties, inhibited TRPV1 currents induced
by capsaicin in dorsal root ganglion neurons, and modulated
TRPV1/TNF-α-mediated synaptic plasticity in the spinal cord,
suggesting a novel analgesic role (Park et al., 2011). The effects of
fatty acids on sensory neurons go beyond receptor signaling. Both
n-6 and n-3 PUFAs promoted neurite outgrowth in sensory neu-
rons from dorsal root ganglia of embryos but also adult and aged
animals (Robson et al., 2010). Enhanced levels of endogenously
synthesized n-3 PUFAs also bestowed beneﬁcial effects in various
aspects. Thus, dorsal root ganglion neurons from Fat-1 expressing
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mice exhibited more resistance to hypoxia and mechanical injury
as compared to neurons from wild-type littermates. Furthermore,
Fat-1 expressing mice showed better functional recovery after sci-
atic nerve crush. The increased endogenous levels of n-3 PUFAs
reduced the expression of the stress sensor activating transcription
factor-3 in dorsal root ganglion neurons, and diminished muscle
atrophy (Gladman et al., 2012). Similarly, our own studies also
reported that the down-regulation of SCD1, which is in charge of
the production of MUFAs such as oleic acid (18:1), triggered accel-
eratedmotor function recovery after sciatic nerve crush, providing
evidence for a new role of this fatty acid desaturase in modulating
the restorative potential of the neuromuscular axis (Hussain et al.,
2013).
The retina possesses a high concentration of n-3 PUFAs, par-
ticularly DHA (22:6 n-3). Many studies have shown that this fatty
acid not only has a structural function but also protects visual
neurons from trauma and disease. Recently, it was noticed that
the retinal dysfunction induced by diabetes could be recovered to
some extent by supplementing DHA (22:6 n-3) extraneously. In
fact, diabetes resulted in reduced levels of n-3 PUFAs, by affecting
n-3 fatty acid desaturase enzymatic activity, so that the provision
of a DHA (22:6 n-3) enriched diet prevented dysfunction of rods
and ameliorated vision (Yee et al., 2010). Also, n-3 PUFA derived
NPD1, together with pigment epithelial-derived growth factor,
promoted corneal nerve regeneration in a rat model of surgi-
cal injury (Cortina et al., 2010, 2012; Kenchegowda et al., 2013).
However, other studies rather obtained contradictory results.
Therefore, augmented levels of DHA (22:6 n-3) bestowed no
protection against retinal degeneration in mice carrying a disease-
causing VPP rhodopsin mutation and expressing Fat-1 (Li et al.,
2009, 2010). In the same way, it was also reported that high levels
of DHA (22:6 n-3) in the retina could generate oxidative stress,
instead of protection, and hence enhance the susceptibility to
degeneration (Tanito et al., 2009).
CONCLUSION
The biological functions of fatty acids have been investigated
intensively during these last years, due to their active involvement
in the physiology of both central and peripheral nervous system.
They promote brain development, ameliorate cognitive functions
in normal and diseased conditions, serve as anti-depressants and
anti-convulsants, bestow protection against traumatic insults, and
elevate repairing processes. At the cellular level, fatty acids stimu-
late gene expression and neuronal activity, and boost synaptogen-
esis and neurogenesis while preventing from neuroinﬂammatory
toxicity and apoptosis (Figure 2). Although the demand for fatty
acids in a healthy body applies to any of them, it can be said that,
in general, excess of SFAs and, to some extent, n-6 PUFAs brings
about negative consequences, whereas MUFAs and n-3 PUFAs
are endowed with rather beneﬁcial properties. In this respect,
the ratio of n-6 to n-3 PUFAs is of special interest. It has been
postulated that a relatively constant n-6:n-3 ratio of about 1:1
constituted a major breakthrough in the expansion of gray mat-
ter in the cerebral cortex of modern human beings (Bradbury,
2011). In the brain, the preservation of an optimal n-6:n-3 ratio
is crucial to the maintenance of the variety of the cellular pro-
cesses in which PUFAs participate (Luchtman and Song, 2013).
During the last century, however, the n-6:n-3 ratio has dramat-
ically increased up to 20–25:1, particularly in Western societies,
because of a high consumption of n-6 PUFAs to the detriment
of n-3 PUFA intake (Simopoulos, 2011). Once the equilibrium
is broken, an excessively high n-6:n-3 ratio would impair normal
brain function and, importantly, predispose to disease (Palacios-
Pelaez et al., 2010). According to what we have exposed herein, a
huge amount of studies have shown the good and the bad side
of different fatty acids in many experimental models of trauma
and disease. Nevertheless, the diversity in modeling any given
physiopathological condition, together with differences in time,
dose and type of fatty acid used to counteract the insult, cer-
tainly account for a number of conﬂicting results concerning the
nature of the observed effects. In addition, it must be taken into
consideration that particular fatty acids are assumed to foster neu-
roprotection but engender indeed a series of collateral deleterious
actions, such as increasing oxidative stress susceptibility or favor-
ing neurodegenerative protein aggregation, which may preclude
the use of these fatty acids under certain (pathological) condi-
tions (Figure 3). Finally, it is also noteworthy that, frequently,
studies used nutritional approaches consisting in giving a speciﬁc
fatty acid or its precursor mixed with others and forming part
of foods relatively more complex than desired, since they also
contain other substances with potential, uncontrolled positive or
negative effects. Taken together, these drawbacks limit the trans-
latability of successful results in terms of neuroprotection obtained
in animal experiments into effective therapeutic interventions in
humans. Numerous epidemiological studies have put fatty acids
forward as key factors contributing toneuropathologybut, in some
cases, discrepant concentrations of fatty acids were reported in
the corresponding diseased brain regions (Table 2). Despite these
constraints, on the basis of these epidemiological studies and sup-
ported by experimental research, there is quite realistic evidence
to envisage that nutritional therapies based on fatty acids can
be of beneﬁt to several neurodegenerative and neurological dis-
eases, such as age-related macular degeneration, cognitive decline,
depression, and some related behavioral disorders (Prior and Gal-
duróz, 2012; Schleicher et al., 2013). More research is needed now
for arriving at the ﬁnal and conclusive result concerning the type
of fatty acid, number of double bonds, origin, particular stage and
proper concentration to achieve beneﬁcial therapeutic potential
against otherwise incurable diseases.
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